IceCure Medical Seeks China Approval for ProSense System
Ticker: ICCM · Form: 6-K · Filed: Jan 27, 2025 · CIK: 1584371
Sentiment: bullish
Topics: regulatory-approval, international-expansion, medical-devices
TL;DR
IceCure Medical files for China approval on ProSense cryoablation system. Big market potential!
AI Summary
On January 27, 2025, IceCure Medical Ltd. announced it has filed for regulatory approval of its ProSense® Cryoablation System in China. This filing is a significant step towards expanding the company's global reach and making its minimally invasive cryoablation technology available to a new patient population.
Why It Matters
Gaining regulatory approval in China, a massive healthcare market, could significantly boost IceCure Medical's revenue and market share, potentially making its cryoablation technology more accessible to millions of patients.
Risk Assessment
Risk Level: medium — Regulatory approvals in new, large markets like China carry inherent risks and uncertainties regarding timelines and final outcomes.
Key Players & Entities
- IceCure Medical Ltd. (company) — Filer of the report and applicant for regulatory approval.
- ProSense® Cryoablation System (company) — The medical device for which regulatory approval is sought.
- China (company) — The target market for regulatory approval.
- January 27, 2025 (date) — Date of the press release and filing.
FAQ
What specific regulatory body in China is IceCure Medical filing with?
The filing does not specify the exact regulatory body in China, but it indicates a filing for regulatory approval.
What is the ProSense® Cryoablation System used for?
The filing refers to it as a 'minimally invasive cryoablation technology' but does not detail its specific medical applications.
When was the press release announcing this filing issued?
The press release was issued on January 27, 2025.
Is this the first time IceCure Medical is seeking approval in China?
The filing does not provide historical context on previous filings in China.
What is the significance of filing in China for IceCure Medical?
Filing for regulatory approval in China represents an expansion into a significant global market for the company's cryoablation technology.
Filing Stats: 305 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2025-01-27 08:40:05
Filing Documents
- ea0228766-6k_icecure.htm (6-K) — 11KB
- ea022876601ex99-1_icecure.htm (EX-99.1) — 9KB
- 0001213900-25-006749.txt ( ) — 22KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ICECURE MEDICAL LTD. Date: January 27, 2025 By: /s/ Eyal Shamir Name: Eyal Shamir Title: Chief Executive Officer 2